{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582407,"version":"4.4.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jdcr.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T12:04:01Z","timestamp":1629288241000},"page":"12-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy"],"prefix":"10.1016","volume":"16","author":[{"given":"Gabrielle","family":"Benesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Andriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10083","key":"10.1016\/j.jdcr.2021.08.005_bib1","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","article-title":"Rituximab as first-line treatment of pemphigus","volume":"389","author":"Schmidt","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jdcr.2021.08.005_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2021.08.005_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study","volume":"32","author":"Toosi","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdcr.2021.08.005_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2021.08.005_bib5","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jdcr.2021.08.005_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/BOR.0b013e3282f5e08d","article-title":"New approaches of B-cell-directed therapy: beyond rituximab","volume":"20","author":"D\u00f6rner","year":"2008","journal-title":"Curr Opin Rheumatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621005506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621005506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:23:17Z","timestamp":1762474997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621005506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":6,"alternative-id":["S2352512621005506"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.08.005","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}